Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center

BACKGROUND: Chimeric antigen receptor T cell (CAR-T) therapy is an effective salvage treatment in relapsed or refractory(r/r) diffuse large B-cell lymphoma (DLBCL), but the impact of hepatitis B virus (HBV) infection has not been studied. METHODS AND RESULTS: Here, 51 patients with r/r DLBCL receivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Danqing, Ping, Nana, Gao, Xin, Zou, Rui, Wang, Peng, Wu, Depei, Jin, Zhengming, Qu, Changju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246493/
https://www.ncbi.nlm.nih.gov/pubmed/37292195
http://dx.doi.org/10.3389/fimmu.2023.1200748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246493/
https://www.ncbi.nlm.nih.gov/pubmed/37292195
http://dx.doi.org/10.3389/fimmu.2023.1200748

Ejemplares similares